Hormonal and pharmacological manipulation of the circadian clock: Recent developments and future strategies

Sleep

Volumn 23, Issue SUPPL. 3, 2000, Pages

  Richardson, Gary ^a   Tate, Barbara ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHRONOBIOTIC; CLORGYLINE; DEUTERIUM; IMIPRAMINE; LITHIUM; MELATONIN; MONOAMINE OXIDASE INHIBITOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; SODIUM; TETRODOTOXIN; THYROTROPIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZOLPIDEM;

ALERTNESS; ANTERIOR HYPOTHALAMUS; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HYPNOSIS; INSOMNIA; JET LAG; LIGHT EXPOSURE; NONHUMAN; PRIORITY JOURNAL; SHIFT WORKER; SLEEP DEPRIVATION; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; ANTIOXIDANTS; CIRCADIAN RHYTHM; CLORGYLINE; HORMONES; HUMANS; HYPOTHALAMUS; IMIPRAMINE; LITHIUM; MELATONIN; MONOAMINE OXIDASE INHIBITORS;

EID: 0034193335     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (133)

1. Addison RG, Thorpy MJ, Roehrs TA, Roth T. Sleep/wake complaints in the general population. Sleep Res 1991;20:112.
2. Allain H, Delahaye Ch, Le Coz F, Blin P, Decombe R, Martinet JP. Post-marketing surveillance of zopiclone in insomnia: analysis of 20513 cases. Sleep, 1991;14(5):408-413.
3. Allain H, Monti J. General safety profile of Zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl 2):21s-29s.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 3rd edition revised. Washington, DC: American Psychiatric Association, 1987.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th edition Washington, DC: American Psychiatric Association, 1993.
7. American Sleep Disorders Association. international classification of sleep disorders: diagnostic and coding manual. Allen, Lawrence: 1990.
8. Antle M E, Marchant et al. Serotonin antagonists and agonists fail to modulate activity-induced phase shifts of circadian rhythms in syrian hamsters. Society for Neuroscience Abstracts 23:240, 1997.
9. Armstrong S M, Melatonin and circadian control in mammals. Experientia 1989;45(10):932-8.
10. Backhaus J, Müller-Popkes K, Hajak G, Voderholzer U, Venegas M, Riemann D, Hohagen F. Neue Ergebnisse zur Prävalenz von Insomnien und ihrer Behandlung in der Hausarztpraxis. Psycho 1996;22:631-637.
11. Badia P. Memories in sleep: Old and new. In: RR Bootzin, JF Kihlstrom, DL Schacter, eds. Sleep and Cognition. Washington, DC: American Psychological Association, 1990:67-76.
12. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(suppl):34-39.
13. Bensimon G, Foret J, Warot D, Lacomblez L, Thiercelin JF, Simon P. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg flunitrazepam 2mg and placebo. Br J Clin Pharmac 1990;30:463-469.
14. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Pharmacol 1990;5(Suppl 2):137-145.
15. Biello SM, Janik D, et al. Neuropeptide Y and behaviorally induced phase shifts. Neuroscience 1994;62(1): 273-9.
16. Bixler EO, Kales A, Soldatos C, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257-1262.
17. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-418.
18. Buysse DJ, Reynolds CFIII, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the international classification of sleep disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep 1994;17:630-7.
19. Caroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry 1982; 140: 292-304.
20. Cassone V M, Roberts M H et al. Effects of melatonin on 2-deoxy-[1-14C]glucose uptake within rat suprachiasmatic nucleus. American Journal of Physiology 1988;255(2 Pt 2): R332-7.
21. Clarenbach P, Steinberg R, Weeß HG, Berger M . Recommendations for the diagnosis and therapy of insomnia. German Society of Sleep Research and Sleep Medicine. Nervenarzt 1995;66:723-729.
22. Cluydts R, Peeters K, De Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998;26: 13-24.
23. Copinschi G, Akseki E, Moreno-Reyes R, Leproult R, L'Hermite-Balériaux M, Caufriez A, Vertongen F, Van Cauter E. Effects of bedtime administration of zolpidem on circadian and sleep-related normal profiles in normal women. Sleep 1995;18(6):417-424.
24. Costa E Silva J, Chase M, Sartorius N, Roth T. An overview of insomnias and related disorders - recognition, epidemiology, and rational management. Sleep 1996;19(5):412-416.
25. Crick F, Mitchison G. REM sleep and neural nets. Behav Brain Res 1995;69:147-155.
26. Czeisler, C. A. The effect of light on the human circadian pacemaker. Ciba Foundation Symposium, 1995;183: 254-90.
27. Daan, S. and C. Pittendrigh. A functional analysis of circadian pacemakers in nocturnal rodents. III. Heavy water and constant light: homeostasis of frequency? Journal of Comparative Physiology, 1976;106: 267-290.
28. Dawson D, Encel N, et al. (1995). Improving adaptation to simulated night shift: timed exposure to bright light versus daytime melatonin administration. Sleep 1995;18(1): 11-21.
29. Dinges D. Are you awake? Cognitive performance and reverie during the hypnopompic state. In: RR Bootzin, JF Kihlstrom, DL Schacter, eds. sleep and cognition., Washington, DC: American Psychological Association, 1990:159-175.
30. Dinges DF, Kribbs NB. Performing while sleepy: effects of experimentally induced sleepiness. In: TH Monk, ed. Sleep, sleepiness and performance, New York: John Wiley & Sons, 1991;97-128.
31. Dujardin K, Guieu JD, Leconte-Lambert C, Leconte P, Borderies P, de La Giclais B. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions: a study of untreated insomniacs. Pharmacopsychiat 1998;31:14-18.
32. Duncan W C, Jr. Circadian rhythms and the pharmacology of affective illness. Pharmacology & Therapeutics, 1996;71(3):253-312.
33. Edgar D, Dement W, et al. Effect of SCN-lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. Journal of Neuroscience 1993;13:1065-1079.
34. Edinger JE, Fins Al, Sullivan RJ Jr, et al. Do our methods lead to insomniacs' madness? Daytime testing after laboratory and home based polysomnographic studies. Sleep 1997;20:1127-1134.
35. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders - an opportunity for prevention? JAMA 1989; 262: 1479-1484.
36. Gaillard JM. Le sommeil, ses mécanismes, ses troubles. Paris, France: Doin, 1990.
37. Gillen M, Li P, et al. The development of a melatonin receptor affinity ligand. Society for Neuroscience Abstracts 1997;23:1069.
38. Gislason T, Almquist M. Somatic disease and sleep complaints. Acta Med Scand 1987;221:475-81.
39. Guilleminault C, Dement WC. Amnesia and disorders of excessive daytime sleepiness. In: R Drucker-Colin, J McGaugh,eds. Neurobiology of sleep and memory. New York: Academic Press, 1997:439-456.
40. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998;13:157-167.
41. Hajak G, Clarenbach P, Fischer W, Haase W, Rüther E. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 1994;9:251-261.
42. Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B, Broocks A, Rüther E. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psy Clin Neurol Sci 1998;248:148-156.
43. Hajak G, Müller-Popkes K, Backhaus J, Schramm E, Riemann D, Hohagen F. Education of primary physicians in sleep medicine: effects on diagnostic and therapeutic decision-making in the primary care setting [abstract]. J Sleep Res 1996;5:83.
44. Hajak G, Müller-Popkes K, Riemann D, Mayer G, Lauer C et al. Psychological, psychotherapeutic and other non-pharmacological forms of therapy in the treatment of insomnia. Fortschr Neurol Psychiat 1997;65: 133-144
45. Hajak G, Rodenbeck A. Clinical management of patients with insomnia: The role of Zopiclone. Pharm Econ 1996;1:29-38
46. Hajak G, Rodenbeck A, Huether G, Bandelow B, Herrendorf G, Staedt J, Rüther E. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996;29:187-192.
47. Hajak G, Rüther E. Insomnie. Berlin Heidelberg: Springer, 1995.
48. Hennevin E, Hars B, Maho C, Bloch V. Processing of learned information in paradoxical sleep: relevance for memory. Behav Brain Res 1995;69:125-135.
49. Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice: A longitudinal study. Eur Arch Psych Clin Neurosci 1993;242:329-336.
50. Horne J. Why we sleep. New York: Oxford University Press, 1998:13-750.
51. International Classification of Sleep Disorders. Diagnostic and coding manual. Diagnostic classification steering committee, Thorpy MJ, Chairman. Rochester, MN: American Sleep Disorders Association, 1990.
52. Jamieson A, Zammit G, Walsh J, MacIntyre J, Allard S, Roth-Schechter B. Abstracts of the European College of Neuropsychopharmacology. (Paris, France) Eur Neuropsychopharmacol 1998;(Suppl. 2): S294-S295.
53. Jenkins JG, Gallenback KM. Obliviscence during sleeping and waking. Am J Psych 1924;35:605-612.
54. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aid sleep in early adulthood. Sleep 1998;21:178-86.
55. Johnson LC, Spinweber CL. Quality of sleep and performance in the Navy: A longitudinal study of good and poor sleepers. In: C Guilleminault, E Lugaresi, eds. Sleep/wake disorders: natural history, epidemiology, and long-term evolution. New York: Raven Press, 1983:13-28.
56. Karacan I, Thornby JI, Anch M, et al. Prevalence of sleep disturbance in a primarily urban Florida county. Soc Sci & Med 1976;10:239-244.
57. Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general adult population. Arch Intern Med 1992;1541634-7.
58. Kripke DF, Simons RN, Carfinkel L, Hammond, E. Short and long term sleep ans sleeping pills: is increased mortality associated? Arch Gen Psychiatr 1979;36:103-116.
59. Kuep W. Zolpidem and Zoplicon: Geringeres Mißbrauchspotential verliehen mit Benzodiazepin-Hypnotika. Psychopharmakotherapie 1998;5 Jahrgang/ Heft 4.
60. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998;Dec.10(6):425-440.
61. Lavie P. Sleep habits and sleep disturbances in industrial workers in Israël: main findings and some characteristics of workers complaining of excessive daytime sleepiness. Sleep 1981;4:147-158.
62. Léger D. The cost of sleep related accidents: a report for the national commission of sleep disorders research. Sleep 1994;17:84-93.
63. Léger D, Janus C, Pellois A, Dreyfus JP. Using DSMIV to assess insomnia in epidemiological surveys. Sleep Research 1995;24A:48.
64. Léger D, Janus C, Pellois A, et al. Sleep morning alertness and quality of life in subjects treated with zopiclone and in good sleepers. Study comparing 167 patients and 381 good sleepers. Eur Psychiatry 1995; 10(Suppl. 3):99s-102.
65. Léger D, Le Pen C, Thébault C, et al. Economical consequences of insomnia. Sleep Res 1997;26:412 (abstract).
66. Leger D, Levy E, Paillard M. The direct costs of insomnia in France. Sleep 1999;22(sup 2):S394-S401.
67. Léger D, Quera-Salva MA, Philip P Health-related quality of life in patients with insomnia treated with zopiclone. PharmacoEconomics 1996;10(Suppl):39-44
68. Leigh JP. Employee and job attributes as predictors of absen-teeism in a national sample of workers: the importance of health and dangerous conditions. Soc Sci Med 1991;33:127-137.
69. Lewy A J, Ahmed S, et al. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiology International 1992;9(5):380-92.
70. Lindberg E, Janson C, Gislason T, et al. Sleep disturbances in a young adult population: can gender differences be explained by differences in psychological status? Sleep 1997;20:381-7.
71. Lister RD. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985;9:87-94.
72. Liu, C, D R Weaver et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19(1):91-102.
73. Lovenberg TW, Baron BM, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993;11:449-58.
74. Lugaresi E, Cirignotta F, Zucconi M, et al. Good and poor sleepers: An epidemiologic survey of the San Marino population. In: C Guilleminault, E. Lugaresi, eds. Sleep/wake disorders: natural history epidemiology, and long-term evolution. New York: Raven Press 1983:1-12.
75. Martin J and Reichlin S. Clinical Neuroendocrinology. Philadelphia,PA F.A.Davis, 1987.
76. McEachron, DL (1987). Antidepressants and food restriction cycles: evidence for multiple pacemakers in rodents. Progress in Clinical & Biological Research 1987;227B:491-506.
77. Mellinger GD, Baiter MB, Uhlenhuth EH. Insomnia and its treatment. Arch Gen Psychiatry 1985;42:225-232.
78. Mendelson WB, Garnett D, Linnoila M. Do insomniacs have impaired daytime functionning? Biological Psychiatry 1984;19:1261-1263.
79. Miller J D, Morin L P, et al. New insights into the mammalian circadian clock. Sleep 1996;19(8): 641-67.
80. Moore R Y. Circadian rhythms: basic neurobiology and clinical applications. Annual Review of Medicine 1997;48: 253-66.
81. Morgan K, Clarke D. Longitudinal trends in late-life insomnia: implications for prescribing. Age Ageing 1997;26(3):179-184.
82. National Commission on Sleep Disorders Research. Wake up America: a national sleep alert, Vol 1. Executive Summary and Executive Report of the National Commission on Sleep Disorders Research. Washington, DC: U.S. Government Printing Office, 1993.
83. National Institute of Mental Health. Consensus development conference. Drugs and insomnia: the use of medications to promote sleep. J Am Med Assoc 1984;251:2410-2414.
84. National Sleep Foundation, Sleep in America: a national Survey of U.S. adults. Los Angeles, CA, 1991.
85. Noble S, Langtry HD, Lamb HM. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998;55(2):277-302.
86. Nowell PD, Buysse DJ, Reynolds CF III, Hauri PJ, Roth T, Stepanski EJ, Thorpy MJ, Bixler E, Kales A, Manfredi RL, Vgontzsas AN, Stapf DM, Houck PR, Kupfer DJ. Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Am J Psychiatry, 1997; 154(10): 1412-1416.
87. Ohayon M. Epidemiological study on insomnia in the general population. Sleep 1996;19:S7-S15.
88. Ohayon MM, Caulet M. Insomnia and psychotropic drug consumption. Prog Neuro-Psychopharmacol Biol Psychiat 1995;19:421-431.
89. Ohayon M, Caulet M. Adinfer: experience of an expert system in psychiatry. In: KC Lun, ed. Medical informatics (MEDINFO 1992). Amsterdam, Elsevier Science, 1992;615-619.
90. Ohayon M, Caulet M, Priest RG, Guilleminault C. DSM-IV and ICSD-90 insomnia symptoms and sleep dissatisfaction. Br J Psychiatr 1997; 171:632-9.
91. Partinen M, Kaprio J, Koskenvuo M, Langinvaino H. Sleeping habits, sleep quality and use of sleeping pills: a population study of 31,140 adults in Finland. In: C Guilleminault, E Lugaresi, eds. Sleep/wake disorders: natural history epidemiology, and long-term Evolution..New-York: Raven Press, 1983:29-36.
92. Patrick DL Health related quality of life in pharmaceutical evaluation: forging progress and avoiding pitfalls. PharmacoEconomics 1992;2:76-8.
93. Prevot, E., Léger, D., De La Giclais, B., Duchossoy, L., Badet, D., Paillard, M. Fighting against "jet-lag": a double blind study on the effects of zolpidem and behavior countermeasures in 58 business travellers. Sleep 1998;21(3 Suppl): 205.
94. Prosser R A, Miller J D, et al. A serotonin agonist phase-shifts the circadian clock in the suprachiasmatic nuclei in vitro. Brain Research 1990;534(1-2):336-9.
95. Quera-Salva MA, Orluc A, Goldenberg F, Guilleminault C. Insomnia and use of hypnotics: Study of a French population. Sleep 1991;14:386-391.
96. Redman J R and Armstrong S M. Reentrainment of rat circadian activity rhythms: effects of melatonin. Journal of Pineal Research 1988;5(2):203-15.
97. Richardson, G S. and H. V. Malin. Circadian rhythm sleep disorders: pathophysiology and treatment. Journal of Clinical Neurophysiology 1996;13(1):17-31.
98. Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharmacology 1994;116:130-134.
99. Roehrs T, Zorick FJ, Sicklesteel JM, Wittig RM, Hartse KM, Roth T. Effects of hypnotics on memory. J Clin Psychopharm 1983;3:310-313.
100. Roth T. Social and economic consequences of sleep disorders. Sleep 1996;19:S46-S47.
101. Roth T, Roehrs T, Bonahoom A, Rosekind M, Koshorek G, Rosenthal L. Cumulative effects of sleep loss. Sleep 1998;12:S239 (abstract).
102. Roth T, Roehrs TA, Carskadon MA, Dement WC. Daytime sleepiness and alertness. In: Kryger M H, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 1994;40-49. Philadelphia, PA: W.B. Sauders Co, 1994:40-49.
103. Roth T, Roehrs T, Zwyghuizen-Doorenbos A, Stepanski E, Wittig R. Sleep and memory. In: Hindmarch I, Ott H, eds. Benzodiazepine receptor ligands, memory and information processing, [NEED LOCATION; PUBLISHER] 1988;140-145.
104. Ruiz MA, Baca E. Design and validation of the "quality of life" questionnaire (Cuestionario de Cualidad de Vida, CCV): a generic health-related perceived quality of life instrument. Eur J Psychol Assess 1993; 9:19-32.
105. Schramm E, Hohagen F, Käpler C, et al. Mental comorbidity of chronic insomnia in general practice attenders using DSM-III-R. Acta Psychiatr Scand, 1995;91:10-17.
106. Schwartz W J, Gross R A, et al. The suprachiasmatic nuclei contain a tetrodotoxin-resistant circadian pacemaker. Proceedings of the national academy of sciences of the United States of America 1987;84(6): 1694-8.
107. Simen S, Hajak G, Schlaf G, Westenhöfer J, Rodenbeck A, Bandelow B, Pudel V, Rüther E. Chronic sleep complaints. Results of a representative survey in Germany. Nervenarzt 1995;66:686-695.
108. Sleath B, Collins T. Physicians responses to an educational intervention on improving their long-term prescription of sedatives. Patient Educ Couns 1997;31(3):215-222.
109. Squire LR. Memory and brain. New York: Oxford University Press, 1987.
110. Steiger A, von Bardeleben U, Herth T, Holsboer F. Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery. J Affective Disord 1989;16:189-195.
111. Stepanski E, Zorick F, Rohers T, et al. Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep 1988;11:54-60.
112. Stephens DN, Sanger DJ. The abuse and dependence liabilities of zolpidem. In: Freeman H, Puech AJ, Roth T, eds. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996;73-86.
113. Stoller MK. Economic effects of insomnia. Clinical Therapeutics 1994; 16:263-287.
114. Tulving E, Schacter DL. Priming and human memory systems. Science 1990;247:301-306.
115. Undén M and Rtoh Schlechter B. Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry 1996; 11(Suppl. 1):21s-30s.
116. Üstün TB, Goldberg D, Cooper J, Simon GE, Sartorius N. New classifications for mental disorders with management guidelines for use in primary care: ICD-10 PHC chapter five. Br J Gen Pract 1995;45(393):211-215.
117. Üstün T, Sartorius N. Mental Illness in General Health Care: an international study. London: John Wiley & Sons, 1995.
118. Walsh JK, Engelhardt CL, Hartman PG. The direct economic cost of insomnia. In: Nutt D, Mendelson W, eds. Hypnotics and anxiolytics: bailliere's clinical psychiatry. London: Bailliere Tindall, 1995:369-81.
119. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United State for 1995. Sleep, 1999 22 (suppl 2):S386-S393.
120. Walsh JK, Fillingim JM. Role of hypnotic drugs in general practice. Am J Med 1990;88 (Suppl 3A):34S-38S.
121. Walsh JK, Sugerman JL. Disorders of initiating and maintaining sleep in adult psychiatric disorders.In: Kryger M, Roth T, Dement WC, eds. Principles and practice of sleep medicine. Philadelphia, PA: WB Saunders, 1989:448-55.
122. Weaver DR and Reppert SM. The mella melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 1996;8(1): 109-12.
123. 1b receptor is not necessary for reproductive and circadian responses to melatonin in Siberian hamsters. Molecular Endocrinology 1996;10(11):1478-87.
124. Wehr T A and Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 1982;15(1):31-9.
125. Weingartner H, Eckardt M, Molchan S, Sunderlant T, Wolkowitz O. Neuropsychological factors in mental disorders and their treatments. Psychopharmacol Bull 1992;28:331-340.
126. Weissman MM, Greenwald S, Nino-Murica G, Dement WC. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry 1997;19:245-250.
127. Welsh DK, Logothetis DE, et al. Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neuron 1995;14(4):697-706.
128. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem and triazolam on performance. Aviation, space and environmental Medicine. 1996;67:2.
129. Wesensten NJ, Balkin TJ, Belenky GL. Effects of administration of zolpidem versus triazolam on memory. Eur J Clin Pharm 1995;48:115-122.
130. Wesensten NJ, Balkin TJ, Davis HQ, Belenky GL. Reversal of triazolam-and zolpidem-induced memory impairment by flumazenil. Psychopharmacology 1995;121:242-249.
131. Wirz-Justice A, Groos G, et al. The neuropharmacology of circadian timekeeping in mammals. In: Vertebrate circadian systems. Aschoff J, Daan S, and Groos G, eds. Berlin, Springer-Verlag: 1982;183-193.
132. World Psychiatric Association. Task force on sedative hypnotics: report. Eur Psychiatry 1993;8:45-49.
133. Zorick F. Insomnia. In: Hauri P, ed. Case studies in insomnia. New York: Plenum, 1991:483-485.